Hopf H B, Grote B, Becker H, Breulmann M
Zentrum für Anaesthesiologie, Unfallchirurgie der Heinrich-Heine Universität Düsseldorf.
Anaesthesist. 1990 Jan;39(1):50-2.
We report a patient with massive perioperative pulmonary embolism (stage IV) and cardiac arrest who was successfully treated with recombinant tissue plasminogen activator (rt-PA). Thrombolytic therapy was started with 25 mg rt-Pa over 15 min followed by another 25 mg over 45 min. During the next 5 h 50 mg were infused, and thereafter an additional 50 mg over 24 h. No major alterations in the plasmatic coagulation profile were noted. With the exception of moderate blood loss from one puncture site, no further bleeding complications occurred. The relevance of this new thrombolytic agent in the perioperative management of acute, life-threatening pulmonary embolism is discussed.
我们报告了一名患有围手术期大面积肺栓塞（IV期）并发生心脏骤停的患者，该患者接受重组组织型纤溶酶原激活剂（rt-PA）治疗成功。溶栓治疗开始时，先在15分钟内静脉注射25mg rt-PA，随后在45分钟内再注射25mg。在接下来的5小时内输注50mg，之后在24小时内再输注50mg。血浆凝血指标未见重大改变。除一个穿刺部位有中度失血外，未发生其他出血并发症。本文讨论了这种新型溶栓剂在围手术期急性、危及生命的肺栓塞管理中的相关性。
